Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 12/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 3/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849194 | 1.00 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2141390 | 0.89 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL29616337 | 0.89 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL8763355 | 0.83 | MIF (0.56) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL9438264 | 0.79 | GABRA1 (0.39) | ALDH1A1CYP3A4GABRA1GABRB2TSHR | |
| SCHEMBL9715358 | 0.79 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1457250 | 0.79 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL13525501 | 0.79 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2564569 | 0.75 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL3933178 | 0.75 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-115093418-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115073476-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-113943297-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-109311886-B | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3475282-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475281-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| CN-109348716-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-109311886-A | Novel [1,2,3] triazol [4,5-d] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2018015088-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015088-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017220517-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | CNR2, CNR1, P2RY2 | MIF 4702/4885TRPA1 279/4885ALDH1A1 2101/4885 |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | MIF 3639/4885TRPA1 1697/4885ALDH1A1 267/4885 |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | CNR2, CNR1, P2RY2 | MIF 4702/4885TRPA1 279/4885ALDH1A1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.